In vivo administration of serum thymic factor (FTS) prevents EMC-D virus-induced diabetes and myocarditis in BALB/cAJcl mice.
The effect of serum thymic factor (FTS) on the D-variant of encephalomyocarditis (EMC-D) virus-induced diabetes and myocarditis in BALB/cAJcl mice was investigated. Mice pretreated with 50 or 10 micrograms of FTS were infected with 10 or 10(3) PFU of EMC-D virus. In the mice inoculated with 10 PFU of virus, 40% developed diabetes on post-infection day (PID) 14, whereas those treated with FTS (50 micrograms/administration) on day 2 and 1 before infection did not develop diabetes. FTS (10 micrograms)-pretreated mice developed diabetes. In histological observation, FTS non-treated mice which developed diabetes showed severe necrosis and inflammation of mononuclear cells in the islets of Langerhans and myocardia on 19 PID. Mice pretreated with 50 micrograms of FTS, however, manifested mild islet degeneration without any myocardial inflammation. Furthermore, in FTS non-treated mice, immunohistological staining showed a loss of insulin granules. This loss was markedly reversed and insulin granules remained largely intact in FTS-pretreated mice. Viral titers in pancreas of FTS-pretreated mice approximated well to those of non-treated mice on PID 4, 7 and 19. In mice inoculated with higher titer of EMC-D virus (10(3) PFU), however, 50 micrograms of FTS pretreatment did not change the course of these acute pathological developments (diabetes and myocarditis observed from PID 4).
Mizutani
M
M
Department of Molecular Immunology, University of Tokyo, Japan.
El-Fotoh
M
M
Mori
M
M
Ono
K
K
Doi
K
K
Awaya
A
A
Matsumoto
Y
Y
Matsumoto
Y
Y
Onodera
T
T
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D018188:Cardiovirus Infections / Q000473:pathology / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D003922:Diabetes Mellitus, Type 1 / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D004334:Drug Administration Schedule; D004686:Encephalomyocarditis virus / Q000254:growth & development; D006321:Heart / Q000821:virology; D007515:Islets of Langerhans / Q000473:pathology / Q000821:virology; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D009205:Myocarditis / Q000473:pathology / Q000517:prevention & control* / Q000821:virology*; D009206:Myocardium / Q000473:pathology; D010179:Pancreas / Q000473:pathology / Q000821:virology; D013935:Thymic Factor, Circulating / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D001786:Blood Glucose; D013935:Thymic Factor, Circulating